Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629497 · ClinicalTrials.gov registry record · Early Phase 1
Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus
A Early Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
NCT02629497: Completed Early Phase 1 study, sponsored by University of Michigan.
NCT02629497 is a Early Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 90 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02629497, a Early Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post-menopausal women with type 2 diabetes mellitus and healthy post-menopausal women will be treated with omega-3 and omega-6 fatty acid supplements to determine protection from platelet activation and thrombosis in this high risk population.
Primary Outcome
decreased platelet activity ex vivo translating to protection from clot formation in vivo
Interventions
- DIETARY_SUPPLEMENT Fish Oil
- DIETARY_SUPPLEMENT Primrose oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06 |
| Phase | Early Phase 1 |
What the finished NCT02629497 record still lists
NCT02629497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 2 interventions - of which Fish Oil is the first listed.
NCT02629497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02629497 about?
NCT02629497 is a clinical study titled "Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus". This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post...
What is the current status of trial NCT02629497?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2015-11. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02629497?
The interventions under investigation include: Fish Oil (DIETARY_SUPPLEMENT), Primrose oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02629497?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02629497's enrollment target sits among peer trials
90 233rd of 2000 higher than 1,753 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia